RecruitingNot Applicable

Study on the Use of Lateral Decubitus Position in Left Breast Cancer Patients Undergoing Adjuvant Radiotherapy

China86 participantsStarted 2025-04-14

Plain-language summary

A Prospective Study on the Application of Lateral Decubitus Position in Patients with Left Breast Cancer Undergoing Adjuvant Radiotherapy

Who can participate

Age range18 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Voluntary signing of the informed consent form * Female patients aged 18-70 years * Newly diagnosed left-sided breast cancer confirmed by histopathology * No evidence of distant metastasis * Undergoing modified radical mastectomy or breast-conserving surgery * ECOG performance status of 0, 1, or 2 * Tolerance to radiotherapy * Radiation field covering the entire left breast/chest wall ± regional lymphatic drainage area Exclusion Criteria: * Bilateral breast cancer at diagnosis * History of breast reconstruction or implant placement on the affected side * Prior radiotherapy to the chest or supraclavicular region * Patients deemed unsuitable for the study based on the investigator's judgment

What they're measuring

Radiotherapy Planning Dose-Volume Parameter -Volume of 5Gy heart dose

Timeframe: From study participation to the completion of the radiotherapy plan up to 2 years

Radiotherapy Planning Dose-Volume Parameter -Max dose of LAD

Timeframe: From study participation to the completion of the radiotherapy plan up to 2 years

Radiotherapy Planning Dose-Volume Parameter -mean heart dose

Timeframe: From study participation to the completion of the radiotherapy plan up to 2 years

Major Cardiovascular Events

Timeframe: From the initiation of radiotherapy to 2 years after its completion.

Subclinical Cardiovascular Events- Left ventricular ejection fraction (LVEF)

Timeframe: From the initiation of radiotherapy to 2 years after its completion.

Subclinical Cardiovascular Events- Left ventricular diastolic dysfunction

Timeframe: From the initiation of radiotherapy to 2 years after its completion.

Trial details

NCT IDNCT06902051

SponsorNanfang Hospital, Southern Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-04-30

Contact for this trial

hongmei Wang, phD

13189092896 hongmeiw18@163.com

View on ClinicalTrials.gov More Breast Cancer Early Stage Breast Cancer (Stage 1-3) trials

Who can participate

Age range18 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Radiotherapy Planning Dose-Volume Parameter -Volume of 5Gy heart dose

Timeframe: From study participation to the completion of the radiotherapy plan up to 2 years

Radiotherapy Planning Dose-Volume Parameter -Max dose of LAD

Timeframe: From study participation to the completion of the radiotherapy plan up to 2 years

Radiotherapy Planning Dose-Volume Parameter -mean heart dose

Timeframe: From study participation to the completion of the radiotherapy plan up to 2 years

Major Cardiovascular Events

Timeframe: From the initiation of radiotherapy to 2 years after its completion.

Subclinical Cardiovascular Events- Left ventricular ejection fraction (LVEF)

Timeframe: From the initiation of radiotherapy to 2 years after its completion.

Subclinical Cardiovascular Events- Left ventricular diastolic dysfunction

Timeframe: From the initiation of radiotherapy to 2 years after its completion.